Germany's pharma leaders warn of global competitiveness crisis amid policy pressures
Five major pharmaceutical and biotechnology associations have urged Federal Health Minister Nina Warken to act swiftly. They warn that Germany's position as a global leader in the sector is under threat. Their call follows growing concerns over recent policy changes and external economic pressures.
The groups highlighted several risks facing the industry. They pointed to Germany's heavy reliance on China for essential drug ingredients and advanced technologies. At the same time, they warned that U.S. trade policies and drug pricing rules could weaken the country's competitive edge.
The associations also criticized the Statutory Health Insurance (GKV) Financial Stabilization Act. According to them, the law has created instability and uncertainty within the sector. However, they acknowledged that the latest Pharma Dialogue had helped rebuild some confidence among stakeholders.
In their appeal, the organizations stressed the need for long-term structural reforms. They claimed to have submitted detailed proposals but had yet to receive any official response. Their focus remains on preventing poorly planned cost-cutting measures, such as aggressive price competition for patented drugs or stricter volume-based pricing rules.
The groups called for a unified, cross-departmental strategy. Such a plan, they argued, would address the broader market challenges facing Germany's pharmaceutical industry and secure its future growth.
The associations' warnings come as the sector faces both domestic and international pressures. Without targeted reforms, they argue, Germany's ability to compete globally could decline. The government has yet to outline concrete steps in response to their proposals.
